ReportsnReports.com added Spinal Cord Injury - Pipeline Review, H1 2017 report provides comprehensive information on the therapeutics under development for Spinal Cord Injury, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects.

Inquire for Complete Spinal Cord Injury Pipeline Review H1 2017 Report at http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=1010756

Description of Report:
Spinal Cord Injury Pipeline Review H1 2017 pipeline guide also reviews of key players involved in therapeutic development for Spinal Cord Injury and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 6, 8, 1, 24 and 6 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 14 and 2 molecules, respectively.

Spinal cord injury (SCI) is defined as damage or trauma caused to the spinal cord. SCI can lead to loss or impaired function resulting in reduced mobility or feeling. It is usually caused by trauma, transverse myelitis, polio, spina bifida or Friedreich's ataxia.

Key Companies Analysed In Report: AbbVie Inc, Acorda Therapeutics Inc, Aevi Genomic Medicine Inc, Apollo Endosurgery Inc, Asterias Biotherapeutics Inc, Athersys Inc, BioArctic AB, BioAxone BioSciences Inc, CSL Ltd, Genervon Biopharmaceuticals LLC, Histocell SL, Kadimastem Ltd, Kringle Pharma Inc, MandalMed Inc, Mapreg SAS, Neuralstem Inc, Neuronax SAS, New World Laboratories Inc, Omeros Corp, Pharmicell Co Ltd, PixarBio Corp, Protagenic Therapeutics Inc, Remedy Pharmaceuticals Inc, RespireRx Pharmaceuticals Inc, SanBio Inc, Stemedica Cell Technologies Inc, TissueGene Inc, Tumorend LLC, Vertex Pharmaceuticals Inc, Vicore Pharma AB

Get Discount on Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1010756 (This report is available at up to 25% Discount till June 02nd 2017)

Scope: The report provides a snapshot of the global therapeutic landscape of Spinal Cord Injury. The report reviews pipeline therapeutics for Spinal Cord Injury by companies and universities/research institutes based on information derived from company and industry-specific sources. The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages. The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities. The report reviews key player’s involved Spinal Cord Injury therapeutics and enlists all their major and minor projects. The report assesses Spinal Cord Injury therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report summarizes all the dormant and discontinued pipeline projects. The report reviews latest news related to pipeline therapeutics for Spinal Cord Injury.

Report helps to Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies. Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. Identify and understand important and diverse types of therapeutics under development for Spinal Cord Injury. Identify potential new clients or partners in the target demographic. Develop strategic initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics. Devise corrective measures for pipeline projects by understanding Spinal Cord Injury pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Direct Purchase This Report at http://www.reportsnreports.com/purchase.aspx?name=1010756 .

Major Table OF Content

• Number of Products under Development for Spinal Cord Injury, H1 2017 14
• Number of Products under Development for Spinal Cord Injury - Comparative Analysis, H1 2017 15
• Number of Products under Development by Companies, H1 2017 16
• Number of Products under Development by Companies, H1 2017 (Contd..1) 17
• Number of Products under Development by Companies, H1 2017 (Contd..2) 18
• Number of Products under Investigation by Universities/Institutes, H1 2017 19
• Comparative Analysis by Late Stage Development, H1 2017 20
• Comparative Analysis by Clinical Stage Development, H1 2017 21
• Comparative Analysis by Early Stage Development, H1 2017 22
• Products under Development by Companies, H1 2017 23
• Products under Development by Companies, H1 2017 (Contd..1) 24
• Products under Development by Companies, H1 2017 (Contd..2) 25
• Products under Investigation by Universities/Institutes, H1 2017 26

About Us:
Reportsnreports.com is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

Contact Us:
Ritesh Tiwari
2nd Floor, Metropole,
Bund Garden Road,
Pune – 411001,
India.
Tel: + 1 888 391 5441
E-mail: [email protected]